- Home
- MRKR vs SNSE Comparison
MRKR vs SNSE Comparison
Compare MRKR & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- SNSE
- Stock Information
- Founded
- MRKR N/A
- SNSE 2005
- Country
- MRKR United States
- SNSE United States
- Employees
- MRKR N/A
- SNSE N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- MRKR Health Care
- SNSE Health Care
- Exchange
- MRKR Nasdaq
- SNSE Nasdaq
- Market Cap
- MRKR 11.6M
- SNSE 10.5M
- IPO Year
- MRKR N/A
- SNSE 2021
- Fundamental
- Price
- MRKR $0.96
- SNSE $8.41
- Analyst Decision
- MRKR Strong Buy
- SNSE Strong Buy
- Analyst Count
- MRKR 3
- SNSE 4
- Target Price
- MRKR $13.17
- SNSE $72.50
- AVG Volume (30 Days)
- MRKR 2.7M
- SNSE 8.3K
- Earning Date
- MRKR 11-13-2025
- SNSE 11-13-2025
- Dividend Yield
- MRKR N/A
- SNSE N/A
- EPS Growth
- MRKR N/A
- SNSE N/A
- EPS
- MRKR N/A
- SNSE N/A
- Revenue
- MRKR $5,388,071.00
- SNSE N/A
- Revenue This Year
- MRKR N/A
- SNSE N/A
- Revenue Next Year
- MRKR $15.82
- SNSE N/A
- P/E Ratio
- MRKR N/A
- SNSE N/A
- Revenue Growth
- MRKR 44.55
- SNSE N/A
- 52 Week Low
- MRKR $0.81
- SNSE $5.00
- 52 Week High
- MRKR $5.95
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- MRKR 41.99
- SNSE 50.96
- Support Level
- MRKR $0.91
- SNSE $7.93
- Resistance Level
- MRKR $1.02
- SNSE $9.49
- Average True Range (ATR)
- MRKR 0.06
- SNSE 0.58
- MACD
- MRKR 0.02
- SNSE 0.04
- Stochastic Oscillator
- MRKR 72.00
- SNSE 41.08
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).